Immunomodulation seems to be a promising strategy in solid tumors where the PD-1/PD-L1 inhibitory pathway can be misused to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. This evidence concerns the gene CD274 and neoplasm.